We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

REL:LSERELX PLC Analysis

Data as of 2026-05-24 - not real-time

£2,447.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

RELX trades at 2,447 p, sitting below its 20‑day (2,540.65 p) and 50‑day (2,549 p) simple moving averages, with a bearish MACD histogram (‑7.37) and a neutral‑to‑slightly‑oversold RSI of 42.6, signalling short‑term downside pressure. The stock’s 30‑day volatility is elevated at ~33 % while its beta is only 0.11, indicating market‑wide moves have limited impact but price swings are pronounced. A discounted cash‑flow model values the company at roughly 1,270 p, implying the market price is more than double intrinsic value, and the upside/downside metric flags a substantial downside potential. Despite this, RELX’s fundamentals remain robust: gross margin of 66 %, operating margin of 31 %, ROE of 70 %, and a sustainable dividend yield of 2.76 % with a payout ratio around 57 %.
The recent launch of a £350 million tranche in its 2026 share‑buyback programme adds a modest catalyst, and analysts collectively rate the stock as a “strong buy” with a median target near £3,450. However, the stark valuation gap and bearish technical setup suggest caution. Over the medium to long term, the company’s diversified, high‑margin business model and dividend stability support a hold stance, while short‑term positioning may tilt toward selling into the current over‑extension.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Price below 20‑ and 50‑day SMAs
  • Bearish MACD signal
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strong cash flow and high ROE
  • Sustainable dividend yield
  • Share‑buyback programme adding modest support

Long Term

> 3 years
Neutral
Model confidence: 8/10

Key Factors

  • Diversified, high‑margin business segments
  • Low beta indicating defensive characteristics
  • Consistent dividend payments and low debt‑to‑equity pressure

Key Metrics & Analysis

Financial Health

Revenue Growth1.20%
Profit Margin21.53%
P/E Ratio21.8
ROE70.51%
ROA12.49%
Debt/Equity304.06
P/B Ratio18.8
Op. Cash Flow£2.8B
Free Cash Flow£2.2B
Industry P/E29.7

Technical Analysis

TrendBearish
RSI42.6
Support£2,297.00
Resistance£2,765.00
MA 20£2,540.65
MA 50£2,549.00
MA 200£2,958.74
MACDBearish
VolumeStable
Fear & Greed Index91.61

Valuation

Fair Value£1,269.54
Target Price£3,618.17
Upside/Downside47.86%
GradeOvervalued
TypeValue
Dividend Yield2.76%

Risk Assessment

Beta0.11
Volatility32.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.